slides · global inventory
27 Cost Of Inaction
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 31,900
Current window 21,961-21,990
Pages 1,064
Rows per page 30
Loop
21,961-21,990 of 31,900
10
Comparison of two distinct cohorts: Healthy Volunteers (SAD/MAD) vs. HS/AD Patient Cohort.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
11
Includes both a longitudinal line chart for IRAK4 degradation and a grouped bar chart with a supporting data table for cytokine inhibition.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
12
Includes PK/PD correlation, blood IRAK4 levels, skin exposure, and skin lesion IRAK4 reduction data.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
13
The charts show log2(fold change) for individual patients. The footnote defines the log2(fold change) values in terms of percentage decrease.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
14
Data compares 'All HS Patients' vs 'Moderate to Severe' subgroups across four metrics over 42 days.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
15
The slide includes a disclaimer that the comparison is not head-to-head and uses historical benchmarks.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
16
Data presented as mean +/- S.E. of mean; N=7 patients.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
17
The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
18
The slide provides clinical safety data for the KT-474 drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
19
The slide outlines the status of a partnership with Sanofi and clinical trial timelines.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
20
Includes clinical trial identifiers and definitions of acronyms in the footer.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
06
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
07
The slide uses two waterfall-bridge charts to explain the variance in financial performance metrics.Lakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
08
Lakeland Bancorp | Results Presentation Deck | 16 slidesLakeland Bancorp | Results Presentation Deck | 16 slides · Lakeland Bancorp
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
10
The slide uses a visual timeline/process flow to explain the biological progression of the disease.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide uses data from a 2022 JNCI study to justify the clinical importance of AA detection sensitivity.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
18
The slide uses a list of icons to anchor the clinical impact of the ALSFRS-R scale.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The chart visualizes the reduction in points lost, highlighting a 3.22 point difference (p=0.03).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
03
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
The slide uses a split layout: team members on the left and their associated track record (logos) on the right.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
05
The slide uses a timeline-based pipeline layout to show the progression of two drug candidates.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
Includes a detailed biological pathway diagram created with BioRender.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide demonstrates superior tumor growth inhibition by NXP800 compared to Cisplatin in both resistant and sensitive models.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
The slide uses two line charts with shaded areas to visualize the year-over-year improvement in churn metrics.Rent The Runway | Results Presentation Deck | 30 slides · Rent The Runway
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
The slide uses a mix of brand logos, fashion photography, and bulleted strategic benefits.Rent The Runway | Results Presentation Deck | 30 slides · Rent The Runway
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
Rent The Runway | Results Presentation Deck | 30 slidesRent The Runway | Results Presentation Deck | 30 slides · Rent The Runway
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
Includes a screenshot of the mobile checkout flow as visual proof of the 'Buy Now' feature.Rent The Runway | Results Presentation Deck | 30 slides · Rent The Runway
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
The slide uses a visual gallery of clothing styles to illustrate the performance improvement.Rent The Runway | Results Presentation Deck | 30 slides · Rent The Runway
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit